<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Niaudet, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Olivia Gillion Boyer, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tej K Mattoo, MD, DCH, FRCP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The hemolytic uremic syndrome (HUS) is defined by the simultaneous occurrence of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury [<a href="#rid1">1</a>]. The most common cause of HUS is Shiga toxin-producing <em>Escherichia</em> <em>coli</em> (STEC), and it is one of the main causes of acute kidney injury in children under the age of three years.</p><p>The clinical manifestations and diagnosis of HUS due to STEC (STEC-HUS) in children are presented in this topic review. The treatment and prognosis of this disorder and other causes of HUS in children are presented separately. (See  <a class="medical medical_review" href="/z/d/html/6097.html" rel="external">"Treatment and prognosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children"</a> and  <a class="medical medical_review" href="/z/d/html/89549.html" rel="external">"Overview of hemolytic uremic syndrome in children"</a> and  <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children"</a>.)</p><p>STEC-HUS in adults is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/114693.html" rel="external">"Thrombotic microangiopathies (TMAs) with acute kidney injury (AKI) in adults: CM-TMA and ST-HUS", section on 'Causes of ST-HUS'</a>.)</p><p class="headingAnchor" id="H29383644"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>In the past, HUS had been divided into diarrhea-positive and diarrhea-negative HUS. Diarrhea-positive HUS, also referred to as typical HUS, primarily resulted from STEC infections, and less frequently from <em>Shigella</em> <em>dysenteriae</em> type 1 infection. All other causes of HUS were referred to as atypical HUS or assigned to the diarrhea-negative HUS, even though some patients with non-STEC-associated HUS also presented with diarrhea. Studies on interventions in patients with STEC-HUS may have used the earlier nomenclature of diarrhea-positive or -negative HUS, or typical versus atypical HUS. In addition, verotoxin, an alternate term for Shiga toxin, has been used extensively in the literature.</p><p>For this topic, we use the current classification system. Thus, patients identified as having either typical or diarrhea-positive HUS would be classified as having acquired HUS due to STEC (STEC-HUS). This classification is based on pathophysiological considerations and triggering factors [<a href="#rid2">2</a>], and it is also based largely on research that has provided a better understanding of the underlying causes of HUS, especially those due to genetic mutations in the alternative pathway of complement [<a href="#rid3">3-5</a>]. Classification is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/89549.html" rel="external">"Overview of hemolytic uremic syndrome in children", section on 'Classification'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MICROBIOLOGY</span><span class="headingEndMark"> — </span>STEC-HUS occurs after an infection with Shiga toxin-producing enterohemorrhagic <em>E</em>. <em>coli</em> (STEC) and accounts for almost all the cases of post-diarrheal HUS in the United States [<a href="#rid6">6-9</a>]. In a review of the literature, the risk of developing HUS for patients with acute illness was approximately 0.1 percent, but the risk is greater in children four years and younger [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H608346"><span class="h2">Escherichia coli strains</span><span class="headingEndMark"> — </span>Different <em>E</em>. <em>coli</em> strains have been associated with both sporadic and epidemic STEC-HUS cases throughout the world. Due to the changes observed in the epidemiology of STEC serotypes, microbiological diagnosis needs to be focused on the virulence factors in stools and diagnosis of the individual <em>E</em>. <em>coli</em> strains. STEC fall into two clinically relevant categories: those that contain a gene encoding Shiga toxin 2 (Stx2; with or without a gene encoding Shiga toxin 1 [Stx1]) and those that do not (ie, their only Shiga toxin gene encodes Stx1)  (<a class="graphic graphic_table graphicRef120224" href="/z/d/graphic/120224.html" rel="external">table 1</a>). Stx2 production is associated with HUS [<a href="#rid11">11-13</a>]. In a prospective multicenter study of 4767 children with bloody diarrhea, 34 of 214 with identified STEC infection developed HUS [<a href="#rid12">12,14</a>]. In this cohort of STEC-infected children, the risk of HUS was 0, 24, and 13 percent for STEC gene expression for only Stx1, only Stx2, and both Stx1 and Stx2, respectively.</p><p>The microbiology and diagnoses of STEC infections are discussed separately [<a href="#rid15">15,16</a>]. (See  <a class="medical medical_review" href="/z/d/html/2711.html" rel="external">"Shiga toxin-producing Escherichia coli: Microbiology, pathogenesis, epidemiology, and prevention", section on 'Microbiology'</a> and  <a class="medical medical_review" href="/z/d/html/2714.html" rel="external">"Shiga toxin-producing Escherichia coli: Clinical manifestations, diagnosis, and treatment", section on 'Microbiologic diagnosis'</a>.)</p><p>The <em>E</em>. <em>coli</em> serotype associated with HUS varies regionally and over time. In much of the world, including the United States, Europe, and Latin America, <em>E</em>. <em>coli</em> 0157:H7 has been the most frequent strain associated with HUS in children [<a href="#rid4">4,11,17,18</a>]. Almost all <em>E</em>. <em>coli</em> O157:H7 contain a gene encoding Stx2.</p><p>However, other strains have become more common including O26, O80, O91, O111, O103, O104, O121, and O145, [<a href="#rid4">4,19-23</a>]. A large outbreak of STEC-HUS in Germany was caused by <em>E</em>. <em>coli</em> O104:H4 [<a href="#rid24">24-26</a>]. In Australia, approximately one-half of cases of post-diarrheal HUS are due to <em>E</em>. <em>coli</em> 0111 [<a href="#rid27">27,28</a>]. In addition, there was an outbreak of <em>E</em>. <em>coli</em> 0111 infections in the United States, in which 26 of 156 patients developed HUS [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H699515594"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Shiga toxin-mediated injury to vascular endothelial cells in the kidney, brain, and other organs underlies the pathogenesis of STEC-HUS. These potent cytotoxins are released by bacteria in the gut, then enter the bloodstream and cause endothelial injury by binding to the globotriaosylceramide (Gb3) receptor on the plasma membrane of endothelial cells, podocytes, and proximal tubular cells [<a href="#rid30">30</a>]. Shiga toxin binding to endothelial cells activates complement and platelet thrombus formation on the endothelial cells, leukocyte binding to the endothelial cells, and induces apoptosis. In addition, these endothelial cells become thrombogenic, which initiates microvascular thrombus formation [<a href="#rid31">31</a>]. The pathogenesis of STEC is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/2711.html" rel="external">"Shiga toxin-producing Escherichia coli: Microbiology, pathogenesis, epidemiology, and prevention", section on 'Pathogenesis'</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H1344976401"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>STEC-HUS accounts for over 90 percent of cases of HUS in children. It principally affects children under the age of five years [<a href="#rid4">4</a>]. In addition, HUS complicates 6 to 9 percent of STEC infections. The reported annual incidence in Europe and North America is 0.5 to 0.8 cases per 100,000 children between 15 and 18 years of age and 1.9 to 2.9 cases per 100,000 children 3 to 5 years of age [<a href="#rid4">4,11,32</a>]. The incidence of STEC-HUS in Latin America remains 10 times higher than in other continents (10 to 17 cases per 100,000 children &lt;5 years in Argentina) [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H590291738"><span class="h2">Transmission</span><span class="headingEndMark"> — </span>Although found in other animals, healthy cattle are the main vectors of STEC, with the bacteria present in the cattle's intestine and feces. Infection in humans occurs following ingestion of contaminated undercooked meat, unpasteurized milk or milk products, water, fruits, or vegetables [<a href="#rid33">33</a>]. A case-control prospective study found that consumption of undercooked ground beef or contact with a person with diarrhea were the major risk factors for sporadic cases of HUS [<a href="#rid33">33</a>].</p><p>Secondary human-to-human contamination is also possible [<a href="#rid16">16,33</a>]. Transmission between children in daycare centers is a concern, and outbreaks (STEC O111 and O26) in kindergarten classrooms have been reported [<a href="#rid23">23</a>]. STEC-HUS also occurs in siblings due to the same contamination or due to human-to-human transmission [<a href="#rid33">33</a>]. In addition, there is one case report of neonatal HUS due to maternal transmission from a healthy mother who was an asymptomatic carrier of STEC [<a href="#rid34">34</a>].</p><p>A more detailed discussion on the epidemiology of STEC is found separately. (See  <a class="medical medical_review" href="/z/d/html/2711.html" rel="external">"Shiga toxin-producing Escherichia coli: Microbiology, pathogenesis, epidemiology, and prevention", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">TYPICAL COURSE</span><span class="headingEndMark"> — </span>Children with STEC-HUS typically have a prodromal illness with abdominal pain, vomiting, and diarrhea that generally precedes the development of HUS by 5 to 10 days  (<a class="graphic graphic_figure graphicRef75352" href="/z/d/graphic/75352.html" rel="external">figure 1</a>) [<a href="#rid15">15,16,35,36</a>]. The diarrhea starts out nonbloody and progresses to bloody diarrhea in 60 to 90 percent of cases [<a href="#rid8">8,37</a>]. Associated gastrointestinal complaints may mimic those of ulcerative colitis, other enteric infections, and appendicitis. (See  <a class="medical medical_review" href="/z/d/html/5871.html" rel="external">"Management of mild to moderate ulcerative colitis in children and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/6479.html" rel="external">"Acute appendicitis in children: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5904.html" rel="external">"Lower gastrointestinal bleeding in children: Causes and diagnostic approach"</a>.)</p><p class="headingAnchor" id="H2387296902"><span class="h1">DIAGNOSTIC TRIAD</span><span class="headingEndMark"> — </span>HUS is defined by a prodrome of diarrhea followed by the sudden onset of the following triad  (<a class="graphic graphic_figure graphicRef75352" href="/z/d/graphic/75352.html" rel="external">figure 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Microangiopathic hemolytic anemia with fragmented erythrocytes (ie, schistocytes)</p><p class="bulletIndent1"><span class="glyph">●</span>Thrombocytopenia</p><p class="bulletIndent1"><span class="glyph">●</span>Kidney involvement, indicated by elevated serum creatinine and/or hematuria and proteinuria</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Microangiopathic hemolytic anemia</span><span class="headingEndMark"> — </span>Microangiopathic hemolytic anemia in HUS is caused by nonimmune red blood cell (RBC) destruction due to shearing of the RBCs through platelet microthrombi. It is characterized by the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin levels usually less than 8 g/dL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Negative direct antiglobulin test (formerly referred to as Coombs test).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral blood smear with a large number (up to 10 percent of red cells) of schistocytes caused by RBC fragmentation. Typical shapes of schistocytes include helmet cells and microspherocytes  (<a class="graphic graphic_picture graphicRef70851 graphicRef50715" href="/z/d/graphic/70851.html" rel="external">picture 1A-B</a>).</p><p></p><p>Additional findings of hemolysis include:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased serum indirect bilirubin concentration</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced serum haptoglobin concentration</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated serum lactate dehydrogenase</p><p></p><p>Although hemolysis may recur over a several-week period, there is no correlation between the severity of anemia and the severity of renal disease. (See  <a class="medical medical_review" href="/z/d/html/5932.html" rel="external">"Overview of hemolytic anemias in children"</a> and  <a class="medical medical_review" href="/z/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)", section on 'Microangiopathic hemolytic anemia (MAHA)'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Thrombocytopenia</span><span class="headingEndMark"> — </span>Thrombocytopenia is characterized by a platelet count below 140,000/microL, usually approximately 40,000/microL. Despite this, there is usually no purpura or active bleeding. The degree of thrombocytopenia is unrelated to the severity of renal dysfunction. (See  <a class="medical medical_review" href="/z/d/html/5930.html" rel="external">"Immune thrombocytopenia (ITP) in children: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Kidney involvement</span><span class="headingEndMark"> — </span>The severity of kidney involvement ranges from hematuria and proteinuria to severe acute kidney injury (AKI) and oligoanuria. AKI in patients with STEC-HUS is defined as a reduction in glomerular filtration rate, which typically presents as an elevated serum creatinine. (See  <a class="medical medical_review" href="/z/d/html/6126.html" rel="external">"Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis", section on 'Definition'</a>.)</p><p>Hemoglobinuria/hematuria is a constant finding in patients with STEC-HUS. In one retrospective study, hematuria was present in all children with HUS [<a href="#rid14">14</a>]. All these patients had bloody diarrhea associated with <em>E</em>. <em>coli</em> carrying Shiga toxin 2 (<em>Stx2</em>) alone or in combination with Shiga toxin 1 (<em>Stx1</em>).</p><p>Other clinical findings of kidney involvement may include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe AKI</strong> – Severe AKI occurs in one-half of cases. As many as one-half to two-thirds of patients with HUS require dialysis during the acute phase [<a href="#rid11">11</a>]. Dehydration at the time of admission appears to be associated with a need for dialysis therapy [<a href="#rid38">38</a>]. The prognosis for recovery of renal function is generally favorable, even in patients in whom dialysis therapy was performed. (See  <a class="medical medical_review" href="/z/d/html/6097.html" rel="external">"Treatment and prognosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children", section on 'Prevention'</a> and  <a class="medical medical_review" href="/z/d/html/6097.html" rel="external">"Treatment and prognosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children", section on 'Prognosis'</a>.)</p><p></p><p class="bulletIndent1">AKI in children is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6126.html" rel="external">"Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypertension</strong> – Hypertension is common, particularly after the administration of excess fluids or blood transfusions.</p><p></p><p class="headingAnchor" id="H159969046"><span class="h3">Kidney pathology</span><span class="headingEndMark"> — </span>Renal biopsy is rarely needed, as the diagnosis is made on the basis of clinical findings. Renal biopsy is indicated when the diagnosis is uncertain and the degree of thrombocytopenia is not limiting.</p><p>Pathologically, STEC-HUS is associated with thrombotic microangiopathy (TMA) of the renal glomeruli, which can extend to the afferent arterioles. Three types of involvement of the renal parenchyma are observed [<a href="#rid39">39,40</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A glomerular TMA characterized by a thickening of the capillary walls, with a double-contour appearance due to a widening of the subendothelial space  (<a class="graphic graphic_picture graphicRef63511" href="/z/d/graphic/63511.html" rel="external">picture 2</a>). Endothelial cells are swollen and may obstruct the capillary lumen. The lesions affect the preglomerular arterioles and the glomerular capillaries, and the mesangial matrix has a fibrillar appearance. The glomeruli are enlarged and the capillaries may contain red cells and platelets. Lesions of glomerular thrombotic microangiopathy affect a variable proportion of the glomeruli.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cortical necrosis may be patchy or, more rarely, diffuse and affect the entire superficial cortex. These lesions are observed in the more severe cases of STEC-HUS with prolonged anuria, and they carry a high risk of chronic renal failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although more often observed in cases of non-STEC-HUS, a pattern of predominant arterial TMA can be observed with STEC-HUS. In this pattern of arterial TMA, which is unusual in children with STEC-HUS, arterioles and interlobular arteries are severely affected with intimal edema, necrosis of the arteriolar wall, luminal narrowing, and thrombosis  (<a class="graphic graphic_picture graphicRef54840 graphicRef69687 graphicRef78330 graphicRef75317" href="/z/d/graphic/54840.html" rel="external">picture 3A-D</a>). Glomeruli appear ischemic and shrunken, with splitting of the capillary wall and wrinkling of the glomerular basement membrane. This lesion is responsible for severe hypertension [<a href="#rid41">41</a>].</p><p></p><p class="headingAnchor" id="H8"><span class="h1">OTHER ORGAN INVOLVEMENT</span><span class="headingEndMark"> — </span>HUS commonly affects other organ systems, causing microvascular injury with swollen endothelial cells and microthrombi. Other systems involved may include [<a href="#rid42">42,43</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central nervous system (CNS)</strong> – Manifestations of CNS involvement include altered mental status, seizures, coma, stroke, hemiparesis, and cortical blindness [<a href="#rid44">44</a>]. Major CNS abnormalities are typically seen in up to 20 to 33 percent of cases [<a href="#rid11">11,44,45</a>]. In patients with severe neurologic findings, brain magnetic resonance imaging reveals bilateral hypersignal on T2-weighted and hyposignal on T1-weighted images in the basal ganglia, thalami, and brainstem [<a href="#rid46">46</a>]. Severe CNS involvement is associated with increased mortality.</p><p></p><p class="bulletIndent1">In addition, severe hypertension may result in CNS symptoms and require emergent therapy to decrease blood pressure. The presence of severe hypertension and the response to antihypertensive therapy differentiate CNS involvement due to elevated blood pressure from primary CNS involvement. (See  <a class="medical medical_review" href="/z/d/html/6438.html" rel="external">"Approach to hypertensive emergencies and urgencies in children", section on 'History'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal tract</strong> – Any area from the esophagus to the perianal area can be involved. The more serious manifestations include severe hemorrhagic colitis (which may be misdiagnosed as ulcerative colitis), bowel necrosis and perforation, rectal prolapse, peritonitis, and intussusception [<a href="#rid47">47,48</a>]. Transmural necrosis of the colon may lead to subsequent colonic stricture [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1">Hepatomegaly and/or increased serum transaminases are frequent findings.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac</strong> – Cardiac dysfunction may be due to fluid overload, hypertension, or hyperkalemia. Direct cardiac involvement has also been reported, including thrombotic microangiopathy, myocarditis, and pericardial disease including cardiac tamponade [<a href="#rid50">50-54</a>]. Cardiac ischemia is detected by elevated levels of troponin 1 [<a href="#rid55">55,56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endocrine</strong> – During the acute phase, up to 10 percent of patients develop glucose intolerance. Transient diabetes mellitus may occur, and rarely permanent diabetes mellitus, which may develop years later [<a href="#rid47">47,57,58</a>].</p><p></p><p class="headingAnchor" id="H9172635"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>An expedited and accurate assessment for HUS is required for a patient with a recent history of diarrhea (possibly bloody) who presents with symptoms and signs of a multisystem disorder  (<a class="graphic graphic_algorithm graphicRef141153" href="/z/d/graphic/141153.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H3336016725"><span class="h2">In whom to suspect hemolytic uremic syndrome</span><span class="headingEndMark"> — </span>HUS should be suspected in a child with a recent history of diarrhea (possibly bloody) and signs of systemic illness  (<a class="graphic graphic_algorithm graphicRef141153" href="/z/d/graphic/141153.html" rel="external">algorithm 1</a>), including:</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased urine volume in an adequately hydrated child (indicating kidney injury)</p><p class="bulletIndent1"><span class="glyph">●</span>Recent onset of paleness (indicating anemia) or bruising (indicating thrombocytopenia)</p><p></p><p class="headingAnchor" id="H3547774658"><span class="h3">Patients without diarrhea</span><span class="headingEndMark"> — </span>In a small minority of patients, the characteristic prodrome of diarrhea is absent. In this case, the presence of the diagnostic triad in an age-appropriate child should still lead to the likely diagnosis of STEC-HUS. The lack of diarrhea should prompt consideration of infection of other organs, particularly the urinary tract, with a Shiga toxin-producing organism [<a href="#rid59">59</a>]. The diagnosis of STEC-HUS is confirmed by polymerase chain reaction (PCR) testing on rectal swab and/or urine.</p><p class="headingAnchor" id="H918603531"><span class="h2">Laboratory evaluation</span><span class="headingEndMark"> — </span>The initial laboratory evaluation  (<a class="graphic graphic_algorithm graphicRef141153" href="/z/d/graphic/141153.html" rel="external">algorithm 1</a>) should include:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count to detect any evidence of anemia or thrombocytopenia. In addition to anemia and thrombocytopenia, leukocytosis is common in diarrhea-induced HUS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Kidney function studies including blood urea nitrogen and serum creatinine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urinalysis to detect hematuria and/or hemoglobinuria.</p><p></p><p>In patients with the diagnostic triad of anemia, thrombocytopenia, and kidney involvement (ie, elevated serum creatinine, and/or hematuria and proteinuria), the peripheral smear should be reviewed for evidence of a microangiopathic pattern with a large number of schistocytes and helmet cells  (<a class="graphic graphic_picture graphicRef70851" href="/z/d/graphic/70851.html" rel="external">picture 1A</a> and <a class="graphic graphic_picture graphicRef50715" href="/z/d/graphic/50715.html" rel="external">picture 1B</a>). (See <a class="local">'Microangiopathic hemolytic anemia'</a> above and <a class="local">'Typical course'</a> above.)</p><p class="headingAnchor" id="H29383692"><span class="h2">Testing for STEC infection</span><span class="headingEndMark"> — </span>Patients in whom HUS is suspected should have an evaluation for STEC infection. In our center, testing includes:</p><p class="bulletIndent1"><span class="glyph">●</span>PCR testing for Shiga toxins from a rectal swab or stool specimen. PCR testing can detect the presence of <em>Stx1</em> and/or <em>Stx2</em> genes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stool culture using media to promote the growth of the O157:H7 strain of <em>E</em>. <em>coli</em>. This is typically done with <a class="drug drug_pediatric" data-topicid="12801" href="/z/d/drug information/12801.html" rel="external">sorbitol</a> MacConkey agar enriched with tellurite. Selective media are required to identify non-O157:H7 STEC. (See  <a class="medical medical_review" href="/z/d/html/2711.html" rel="external">"Shiga toxin-producing Escherichia coli: Microbiology, pathogenesis, epidemiology, and prevention", section on 'Microbiology'</a> and  <a class="medical medical_review" href="/z/d/html/2714.html" rel="external">"Shiga toxin-producing Escherichia coli: Clinical manifestations, diagnosis, and treatment", section on 'Microbiologic diagnosis'</a>.)</p><p></p><p class="bulletIndent1">Stool samples should be obtained rapidly, because STEC infection is caused by a low load of organisms, and excretion in the stools lasts only a few days after the onset of diarrhea [<a href="#rid60">60</a>]. If stool cannot be obtained, rectal swabs should be performed [<a href="#rid37">37</a>]. A negative stool culture does not rule out the diagnosis of STEC infection because the bacteria may not be detected by culture from stool samples even if they are present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although failure to detect STEC in the stool of a patient with STEC-HUS is rare, this should not rule out the diagnosis of STEC-HUS. Serum antibodies to lipopolysaccharide of STEC, if available, may aid in the diagnosis of STEC when the stool screen for STEC is negative. These antibodies persist in the serum for several weeks [<a href="#rid61">61</a>].</p><p></p><p class="headingAnchor" id="H9173464"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of STEC-HUS in children is made on clinical grounds based on the characteristic clinical and laboratory findings previously described: a prodrome of diarrhea due to a Shiga toxin-producing bacteria, followed by abrupt onset of the diagnostic triad (see <a class="local">'Typical course'</a> above and <a class="local">'Diagnostic triad'</a> above and <a class="local">'Evaluation'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>Microangiopathic hemolytic anemia</p><p class="bulletIndent1"><span class="glyph">●</span>Thrombocytopenia</p><p class="bulletIndent1"><span class="glyph">●</span>Kidney involvement, indicated by elevated serum creatinine and/or hematuria and proteinuria [<a href="#rid62">62</a>]</p><p></p><p>Diagnosis of STEC-HUS is confirmed by a positive test for Shiga toxin (ie, polymerase chain reaction [PCR] on stool or rectal swab, stool culture). Of note, diarrhea may be absent in a small number of patients with STEC-HUS. The absence of diarrhea should not rule out the diagnosis of STEC-HUS [<a href="#rid59">59</a>]. (See <a class="local">'Evaluation'</a> above.)</p><p>In most patients, treatment is initiated based on the clinical diagnosis of HUS. Renal biopsy, which is rarely needed, may be helpful in selected patients in whom the diagnosis is uncertain and the procedure is not contraindicated by severe thrombocytopenia. (See <a class="local">'Kidney pathology'</a> above and  <a class="medical medical_review" href="/z/d/html/89549.html" rel="external">"Overview of hemolytic uremic syndrome in children"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The constellation of clinical and laboratory findings typical of STEC-HUS in children is similar to that found in other disorders. These include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other enteric infections</strong> – The combination of severe diarrhea and renal insufficiency seen in other enteric infections (such as <em>Salmonella</em>, <em>Campylobacter</em>, <em>Yersinia</em>, amebiasis, and <em>Clostridioides</em> <em>difficile</em>) may be confused with that caused by HUS. The severe abdominal pain, frankly bloody diarrhea, fever, and leukocytosis seen with these infections are similar to the prodrome seen in STEC-HUS. In addition, patients with severe diarrhea can have elevations in serum creatinine and blood urea nitrogen, but this is typically due to volume depletion, not intrinsic renal disease. This constellation of findings in <strong>the absence of </strong>thrombocytopenia and hemolytic anemia distinguishes these enteric infections from HUS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-STEC HUS</strong> – It can be challenging to differentiate STEC-HUS from other causes of HUS because the clinical presentations can be similar. Although non-STEC-HUS does not usually present with a diarrheal prodrome, approximately one-quarter of patients with complement-mediated HUS (the second most common cause of HUS) will have an antecedent trigger of a diarrheal illness. Moreover, some cases of STEC-HUS may not present with colitis and diarrhea. Furthermore, the alternative complement pathway may be transiently activated during the acute phase of STEC-HUS [<a href="#rid63">63,64</a>], and STEC can trigger HUS episodes in patients with complement mutation, mostly in those with membrane cofactor protein (MCP) mutation [<a href="#rid65">65</a>]. Nevertheless, clinical and laboratory manifestations typically differentiate STEC-HUS from the two most common causes of non-STEC-HUS, as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pneumococcal-associated HUS – Affected patients have concurrent serious pneumococcal infection (eg, pneumonia or meningitis) and no evidence of Shiga toxin on stool polymerase chain reaction (PCR) and/or culture. (See  <a class="medical medical_review" href="/z/d/html/89549.html" rel="external">"Overview of hemolytic uremic syndrome in children", section on 'Streptococcus pneumoniae'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complement-mediated HUS – These patients generally have a severe clinical course, recurrent disease, and often a positive family history. Genetic testing or identifying antibodies to complement components confirms the diagnosis of complement-mediated HUS. These patients also have no evidence of Shiga toxin on stool PCR and/or culture. (See  <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children"</a>.)</p><p></p><p class="bulletIndent1"><em>Shigella</em> <em>dysenteriae</em> type 1-associated HUS occurs in India, Bangladesh, and southern Africa. Although the pathogenesis of disease is similar to that of HUS induced by O157 <em>E</em>. <em>coli</em> infection, the disease is usually more severe, with an acute mortality rate of 15 percent and over 40 percent of patients developing chronic kidney disease [<a href="#rid32">32</a>]. <em>Shigella</em> HUS is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2718.html" rel="external">"Shigella infection: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6003.html" rel="external">"Shigella infection: Treatment and prevention in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombotic thrombocytopenic purpura (TTP)</strong> – TTP is rare in children and is characterized by the association of thrombocytopenia, microangiopathic hemolytic anemia, renal involvement, and neurologic symptoms. TTP is secondary to a deficiency of the ADAMS-13 protease which normally cleaves the von Willebrand factor multimers. In children, the ADAMS-13 deficiency is a rare autosomal recessive disorder. In adults, the disease is most often secondary to autoantibodies against ADAMTS13.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disseminated intravascular coagulation (DIC)</strong> – As in STEC-HUS, patients with DIC also have thrombocytopenia, hemolytic anemia, and kidney injury. However, patients with DIC have abnormal coagulation studies (prolongation of the prothrombin time [PT] and activated partial thromboplastin time [aPTT]), and patients with HUS have normal coagulation studies. The distinction between HUS and DIC can be challenging; it is based upon the history and laboratory studies [<a href="#rid66">66</a>]. Contrary to DIC, HUS patients rarely have active bleeding. DIC is associated with intravascular activation of the coagulation cascade, leading to intravascular deposition of fibrin thrombi, the consumption of all the components of this cascade, and microangiopathic hemolytic anemia. As a result, patients with DIC typically have thrombocytopenia, as do patients with STEC-HUS. However, patients with DIC also have elevated D-dimer, normal haptoglobin levels, low circulating levels of fibrinogen and factors V and VIII, and elevation of the PT and aPTT, which is not generally seen in patients with HUS [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/z/d/html/5915.html" rel="external">"Disseminated intravascular coagulation in infants and children"</a> and  <a class="medical medical_review" href="/z/d/html/89549.html" rel="external">"Overview of hemolytic uremic syndrome in children", section on 'Differential diagnosis'</a>.)</p><p></p><p class="headingAnchor" id="H2867867132"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117977.html" rel="external">"Society guideline links: Hemolytic uremic syndrome in children"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/117846.html" rel="external">"Society guideline links: Thrombotic microangiopathies (TTP, HUS, and related disorders)"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology</strong> – Most cases of hemolytic uremic syndrome (HUS) are due to an infection with Shiga toxin-producing <em>Escherichia</em> <em>coli</em> (STEC), which accounts for 90 percent of pediatric cases of HUS. (See <a class="local">'Microbiology'</a> above and <a class="local">'Epidemiology'</a> above and <a class="local">'Kidney pathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Typical course</strong> – Children with STEC-HUS typically have a prodromal illness with abdominal pain, vomiting, and diarrhea (sometimes bloody) that precedes the development of HUS by approximately 5 to 10 days  (<a class="graphic graphic_figure graphicRef75352" href="/z/d/graphic/75352.html" rel="external">figure 1</a>). (See <a class="local">'Typical course'</a> above.)</p><p></p><p class="bulletIndent1">Diarrhea may be bloody or nonbloody. In a small minority of cases, diarrhea may be absent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic triad</strong> – HUS presents suddenly with the following classical findings (see <a class="local">'Diagnostic triad'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Microangiopathic hemolytic anemia</strong> – Hemoglobin levels are usually less than 8 g/dL. Direct antiglobulin test is negative, and the peripheral blood smear is characterized by the large number of schistocytes and helmet cells  (<a class="graphic graphic_picture graphicRef70851 graphicRef50715" href="/z/d/graphic/70851.html" rel="external">picture 1A-B</a>). There is no correlation between the severity of the anemia and the severity of the kidney disease. (See <a class="local">'Microangiopathic hemolytic anemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thrombocytopenia</strong> – Platelet counts are generally around 40,000/microL. There is no correlation between the degree of thrombocytopenia and the severity of the kidney disease. (See <a class="local">'Thrombocytopenia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Kidney involvement</strong> – The severity of kidney involvement ranges from hematuria and proteinuria to acute kidney injury (AKI; ie, elevated serum creatinine), to severe kidney failure and oligoanuria, which occur in one-half of cases. Hypertension is also frequently observed. Although as many as 50 percent of those with HUS require dialysis during the acute phase, the prognosis for recovery of kidney function is generally favorable. (See <a class="local">'Kidney involvement'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other organ involvement</strong> – Other organ systems that may be involved include the central nervous system (CNS), gastrointestinal tract, heart, pancreas, and liver. Severe CNS involvement (eg, seizures, coma, and stroke) is associated with significant mortality. (See <a class="local">'Other organ involvement'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – An expedited and accurate assessment for HUS  (<a class="graphic graphic_algorithm graphicRef141153" href="/z/d/graphic/141153.html" rel="external">algorithm 1</a>) is required for a patient with a recent history of diarrhea (possibly bloody) who presents with symptoms and signs of a multisystem disorder. The initial evaluation comprises a complete blood count to detect any evidence of anemia or thrombocytopenia and renal function studies, including serum creatinine. In those patients with anemia, thrombocytopenia, and elevated serum creatinine, further investigation includes reviewing the peripheral smear for evidence of a microangiopathic pattern with a large number of schistocytes and helmet cells  (<a class="graphic graphic_picture graphicRef70851 graphicRef50715" href="/z/d/graphic/70851.html" rel="external">picture 1A-B</a>) and screening for a STEC infection. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of STEC-HUS in children is generally made on clinical grounds from the characteristic clinical course and laboratory findings. The typical course includes a diarrheal prodrome followed by the sudden onset of the diagnostic triad (see <a class="local">'Diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Microangiopathic hemolytic anemia</p><p class="bulletIndent2"><span class="glyph">•</span>Thrombocytopenia</p><p class="bulletIndent2"><span class="glyph">•</span>Kidney involvement, indicated by elevated serum creatinine and/or hematuria and proteinuria</p><p></p><p class="bulletIndent1">Shiga toxin exposure is confirmed by a positive test for Shiga toxin from either a stool or rectal swab using polymerase chain reaction (PCR), or a positive stool culture. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential for STEC-HUS includes other enteric infections, non-STEC HUS, thrombotic thrombocytopenic purpura (TTP), and disseminated intravascular coagulation (DIC). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16:1035.</a></li><li><a class="nounderline abstract_t">Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G. An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. Clin Kidney J 2019; 12:333.</a></li><li><a class="nounderline abstract_t">Goodship TH, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2017; 91:539.</a></li><li><a class="nounderline abstract_t">Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet 2017; 390:681.</a></li><li><a class="nounderline abstract_t">Boyer O, Niaudet P. Hemolytic-Uremic Syndrome in Children. Pediatr Clin North Am 2022; 69:1181.</a></li><li><a class="nounderline abstract_t">Houdouin V, Doit C, Mariani P, et al. A pediatric cluster of Shigella dysenteriae serotype 1 diarrhea with hemolytic uremic syndrome in 2 families from France. Clin Infect Dis 2004; 38:e96.</a></li><li><a class="nounderline abstract_t">Fitzpatrick M. Haemolytic uraemic syndrome and E coli O157. BMJ 1999; 318:684.</a></li><li><a class="nounderline abstract_t">Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365:1073.</a></li><li><a class="nounderline abstract_t">van de Kar NC, Roelofs HG, Muytjens HL, et al. Verocytotoxin-producing Escherichia coli infection in hemolytic uremic syndrome in part of western Europe. Eur J Pediatr 1996; 155:592.</a></li><li><a class="nounderline abstract_t">Majowicz SE, Scallan E, Jones-Bitton A, et al. Global incidence of human Shiga toxin-producing Escherichia coli infections and deaths: a systematic review and knowledge synthesis. Foodborne Pathog Dis 2014; 11:447.</a></li><li><a class="nounderline abstract_t">Ylinen E, Salmenlinna S, Halkilahti J, et al. Hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli in children: incidence, risk factors, and clinical outcome. Pediatr Nephrol 2020; 35:1749.</a></li><li><a class="nounderline abstract_t">Ardissino G, Possenti I, Vignati C, et al. Is Shigatoxin 1 protective for the development of Shigatoxin 2-related hemolytic uremic syndrome in children? Data from the ItalKid-HUS Network. Pediatr Nephrol 2020; 35:1997.</a></li><li><a class="nounderline abstract_t">Alconcher LF, Balestracci A, Coccia PA, et al. Hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli infection in Argentina: update of serotypes and genotypes and their relationship with severity of the disease. Pediatr Nephrol 2021; 36:2811.</a></li><li><a class="nounderline abstract_t">Ardissino G, Vignati C, Masia C, et al. Bloody Diarrhea and Shiga Toxin-Producing Escherichia coli Hemolytic Uremic Syndrome in Children: Data from the ItalKid-HUS Network. J Pediatr 2021; 237:34.</a></li><li><a class="nounderline abstract_t">Boyce TG, Swerdlow DL, Griffin PM. Escherichia coli O157:H7 and the hemolytic-uremic syndrome. N Engl J Med 1995; 333:364.</a></li><li><a class="nounderline abstract_t">Bell BP, Goldoft M, Griffin PM, et al. A multistate outbreak of Escherichia coli O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience. JAMA 1994; 272:1349.</a></li><li><a class="nounderline abstract_t">Banatvala N, Griffin PM, Greene KD, et al. The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings. J Infect Dis 2001; 183:1063.</a></li><li><a class="nounderline abstract_t">Mody RK, Luna-Gierke RE, Jones TF, et al. Infections in pediatric postdiarrheal hemolytic uremic syndrome: factors associated with identifying shiga toxin-producing Escherichia coli. Arch Pediatr Adolesc Med 2012; 166:902.</a></li><li><a class="nounderline abstract_t">Rivas M, Chinen I, Miliwebsky E, Masana M. Risk Factors for Shiga Toxin-Producing Escherichia coli-Associated Human Diseases. Microbiol Spectr 2014; 2.</a></li><li><a class="nounderline abstract_t">Gould LH, Mody RK, Ong KL, et al. Increased recognition of non-O157 Shiga toxin-producing Escherichia coli infections in the United States during 2000-2010: epidemiologic features and comparison with E. coli O157 infections. Foodborne Pathog Dis 2013; 10:453.</a></li><li class="breakAll">European Centre for Disease Prevention and Control. Surveillance of seven priority food- and waterborne diseases in the EU/EEA, 2010-2012. https://www.ecdc.europa.eu/sites/default/files/documents/AER%20STEC%20-%202021.pdf (Accessed on March 30, 2023).</li><li><a class="nounderline abstract_t">Tozzi AE, Caprioli A, Minelli F, et al. Shiga toxin-producing Escherichia coli infections associated with hemolytic uremic syndrome, Italy, 1988-2000. Emerg Infect Dis 2003; 9:106.</a></li><li><a class="nounderline abstract_t">Bruyand M, Mariani-Kurkdjian P, Le Hello S, et al. Paediatric haemolytic uraemic syndrome related to Shiga toxin-producing Escherichia coli, an overview of 10 years of surveillance in France, 2007 to 2016. Euro Surveill 2019; 24.</a></li><li><a class="nounderline abstract_t">Soysal N, Mariani-Kurkdjian P, Smail Y, et al. Enterohemorrhagic Escherichia coli Hybrid Pathotype O80:H2 as a New Therapeutic Challenge. Emerg Infect Dis 2016; 22:1604.</a></li><li class="breakAll">Centers for Disease Control and Prevention. CDC Statement on Outbreak of STEC O104:H4 infections in Germany, June 1, 2011. www.cdc.gov/media/releases/2011/s0601_ecoligermany.html?s_cid=2011_s0601_ecoligermany (Accessed on June 02, 2011).</li><li><a class="nounderline abstract_t">Frank C, Faber MS, Askar M, et al. Large and ongoing outbreak of haemolytic uraemic syndrome, Germany, May 2011. Euro Surveill 2011; 16.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Community outbreak of hemolytic uremic syndrome attributable to Escherichia coli O111:NM--South Australia 1995. MMWR Morb Mortal Wkly Rep 1995; 44:550.</a></li><li><a class="nounderline abstract_t">Elliott EJ, Robins-Browne RM, O'Loughlin EV, et al. Nationwide study of haemolytic uraemic syndrome: clinical, microbiological, and epidemiological features. Arch Dis Child 2001; 85:125.</a></li><li><a class="nounderline abstract_t">Piercefield EW, Bradley KK, Coffman RL, Mallonee SM. Hemolytic Uremic Syndrome After an Escherichia coli O111 Outbreak. Arch Intern Med 2010; 170:1656.</a></li><li><a class="nounderline abstract_t">Psotka MA, Obata F, Kolling GL, et al. Shiga toxin 2 targets the murine renal collecting duct epithelium. Infect Immun 2009; 77:959.</a></li><li><a class="nounderline abstract_t">Zoja C, Buelli S, Morigi M. Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction. Pediatr Nephrol 2010; 25:2231.</a></li><li><a class="nounderline abstract_t">Bhimma R, Rollins NC, Coovadia HM, Adhikari M. Post-dysenteric hemolytic uremic syndrome in children during an epidemic of Shigella dysentery in Kwazulu/Natal. Pediatr Nephrol 1997; 11:560.</a></li><li><a class="nounderline abstract_t">Vaillant V, Espié E, de Valk H, et al. Undercooked ground beef and person-to-person transmission as major risk factors for sporadic hemolytic uremic syndrome related to Shiga-toxin producing Escherchia coli infections in children in France. Pediatr Infect Dis J 2009; 28:650.</a></li><li><a class="nounderline abstract_t">Stritt A, Tschumi S, Kottanattu L, et al. Neonatal hemolytic uremic syndrome after mother-to-child transmission of a low-pathogenic stx2b harboring shiga toxin-producing Escherichia coli. Clin Infect Dis 2013; 56:114.</a></li><li><a class="nounderline abstract_t">Su C, Brandt LJ. Escherichia coli O157:H7 infection in humans. Ann Intern Med 1995; 123:698.</a></li><li><a class="nounderline abstract_t">Gerber A, Karch H, Allerberger F, et al. Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. J Infect Dis 2002; 186:493.</a></li><li><a class="nounderline abstract_t">Bruyand M, Mariani-Kurkdjian P, Gouali M, et al. Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection. Med Mal Infect 2018; 48:167.</a></li><li><a class="nounderline abstract_t">Balestracci A, Martin SM, Toledo I, et al. Dehydration at admission increased the need for dialysis in hemolytic uremic syndrome children. Pediatr Nephrol 2012; 27:1407.</a></li><li><a class="nounderline abstract_t">Habib R, Levy M, Gagnadoux M, et al. Prognosis of the hemolytic uremic syndrome in children. Adv Nephrol Necker Hosp 1982; 11:99.</a></li><li class="breakAll">Habib R. Pathology of the hemolytic and uremic syndrome. In: Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura, Kaplan BS, Trompeter R, Moake J (Eds), Dekker, New York 1992. p.315.</li><li class="breakAll">Loirat C, Taylor CM. Hemolytic Uremic Syndromes. In: Pediatric Nephrology, 4th ed, Avner ED, Harmon WE, Niaudet P (Eds), Lippincott, Williams &amp; Wilkins, Baltimore 2004. p.887.</li><li><a class="nounderline abstract_t">Khalid M, Andreoli S. Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS). Pediatr Nephrol 2019; 34:2495.</a></li><li><a class="nounderline abstract_t">Siegler RL. Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome. J Pediatr 1994; 125:511.</a></li><li><a class="nounderline abstract_t">Nathanson S, Kwon T, Elmaleh M, et al. Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2010; 5:1218.</a></li><li><a class="nounderline abstract_t">Bauer A, Loos S, Wehrmann C, et al. Neurological involvement in children with E. coli O104:H4-induced hemolytic uremic syndrome. Pediatr Nephrol 2014; 29:1607.</a></li><li><a class="nounderline abstract_t">Jeong YK, Kim IO, Kim WS, et al. Hemolytic uremic syndrome: MR findings of CNS complications. Pediatr Radiol 1994; 24:585.</a></li><li><a class="nounderline abstract_t">de Buys Roessingh AS, de Lagausie P, Baudoin V, et al. Gastrointestinal complications of post-diarrheal hemolytic uremic syndrome. Eur J Pediatr Surg 2007; 17:328.</a></li><li><a class="nounderline abstract_t">Rahman RC, Cobeñas CJ, Drut R, et al. Hemorrhagic colitis in postdiarrheal hemolytic uremic syndrome: retrospective analysis of 54 children. Pediatr Nephrol 2012; 27:229.</a></li><li><a class="nounderline abstract_t">Masumoto K, Nishimoto Y, Taguchi T, et al. Colonic stricture secondary to hemolytic uremic syndrome caused by Escherichia coli O-157. Pediatr Nephrol 2005; 20:1496.</a></li><li><a class="nounderline abstract_t">Sanders E, Brown CC, Blaszak RT, et al. Cardiac Manifestation among Children with Hemolytic Uremic Syndrome. J Pediatr 2021; 235:144.</a></li><li><a class="nounderline abstract_t">Rigamonti D, Simonetti GD. Direct cardiac involvement in childhood hemolytic-uremic syndrome: case report and review of the literature. Eur J Pediatr 2016; 175:1927.</a></li><li><a class="nounderline abstract_t">Abu-Arafeh I, Gray E, Youngson G, et al. Myocarditis and haemolytic uraemic syndrome. Arch Dis Child 1995; 72:46.</a></li><li><a class="nounderline abstract_t">Birk PE, Chakrabarti S, Lacson AG, Ogborn MR. Cardiac tamponade as a terminal event in the hemolytic uremic syndrome in childhood. Pediatr Nephrol 1994; 8:754.</a></li><li><a class="nounderline abstract_t">Mohammed J, Filler G, Price A, Sharma AP. Cardiac tamponade in diarrhoea-positive haemolytic uraemic syndrome. Nephrol Dial Transplant 2009; 24:679.</a></li><li><a class="nounderline abstract_t">Askiti V, Hendrickson K, Fish AJ, et al. Troponin I levels in a hemolytic uremic syndrome patient with severe cardiac failure. Pediatr Nephrol 2004; 19:345.</a></li><li><a class="nounderline abstract_t">Thayu M, Chandler WL, Jelacic S, et al. Cardiac ischemia during hemolytic uremic syndrome. Pediatr Nephrol 2003; 18:286.</a></li><li><a class="nounderline abstract_t">Andreoli S, Bergstein J. Exocrine and endocrine pancreatic insufficiency and calcinosis after hemolytic uremic syndrome. J Pediatr 1987; 110:816.</a></li><li><a class="nounderline abstract_t">Nesmith JD, Ellis E. Childhood hemolytic uremic syndrome is associated with adolescent-onset diabetes mellitus. Pediatr Nephrol 2007; 22:294.</a></li><li><a class="nounderline abstract_t">Starr M, Bennett-Wood V, Bigham AK, et al. Hemolytic-uremic syndrome following urinary tract infection with enterohemorrhagic Escherichia coli: case report and review. Clin Infect Dis 1998; 27:310.</a></li><li><a class="nounderline abstract_t">Obrig TG. Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease. Toxins (Basel) 2010; 2:2769.</a></li><li><a class="nounderline abstract_t">Wijnsma KL, van Bommel SA, van der Velden T, et al. Fecal diagnostics in combination with serology: best test to establish STEC-HUS. Pediatr Nephrol 2016; 31:2163.</a></li><li><a class="nounderline abstract_t">Bagga A, Khandelwal P, Mishra K, et al. Hemolytic uremic syndrome in a developing country: Consensus guidelines. Pediatr Nephrol 2019; 34:1465.</a></li><li><a class="nounderline abstract_t">Keir LS, Saleem MA. Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol 2014; 29:1895.</a></li><li><a class="nounderline abstract_t">Poolpol K, Orth-Höller D, Speth C, et al. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. Mol Immunol 2014; 58:77.</a></li><li><a class="nounderline abstract_t">Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013; 8:554.</a></li><li class="breakAll">Marder VJ, Martin SE, Francis CW, Colman RW. Consumptive thrombo-hemorrhagic disorders. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 2nd ed, Colman RW, Hirsh J, Marder VJ, Salzman EW (Eds), Lippincott, Philadelphia 1987. p.975.</li></ol></div><div id="topicVersionRevision">Topic 6081 Version 59.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728781" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31198225" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27989322" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28242109" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Haemolytic uraemic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36880929" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hemolytic-Uremic Syndrome in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15127361" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A pediatric cluster of Shigella dysenteriae serotype 1 diarrhea with hemolytic uremic syndrome in 2 families from France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10073994" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Haemolytic uraemic syndrome and E coli O157.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15781103" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8831084" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Verocytotoxin-producing Escherichia coli infection in hemolytic uremic syndrome in part of western Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24750096" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Global incidence of human Shiga toxin-producing Escherichia coli infections and deaths: a systematic review and knowledge synthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32323005" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli in children: incidence, risk factors, and clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32734345" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Is Shigatoxin 1 protective for the development of Shigatoxin 2-related hemolytic uremic syndrome in children? Data from the ItalKid-HUS Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33604727" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli infection in Argentina: update of serotypes and genotypes and their relationship with severity of the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34197890" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Bloody Diarrhea and Shiga Toxin-Producing Escherichia coli Hemolytic Uremic Syndrome in Children: Data from the ItalKid-HUS Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7609755" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Escherichia coli O157:H7 and the hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7933395" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A multistate outbreak of Escherichia coli O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11237831" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22869280" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Infections in pediatric postdiarrheal hemolytic uremic syndrome: factors associated with identifying shiga toxin-producing Escherichia coli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26104362" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Risk Factors for Shiga Toxin-Producing Escherichia coli-Associated Human Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23560425" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Increased recognition of non-O157 Shiga toxin-producing Escherichia coli infections in the United States during 2000-2010: epidemiologic features and comparison with E. coli O157 infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23560425" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Increased recognition of non-O157 Shiga toxin-producing Escherichia coli infections in the United States during 2000-2010: epidemiologic features and comparison with E. coli O157 infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12533290" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Shiga toxin-producing Escherichia coli infections associated with hemolytic uremic syndrome, Italy, 1988-2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30808442" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Paediatric haemolytic uraemic syndrome related to Shiga toxin-producing Escherichia coli, an overview of 10 years of surveillance in France, 2007 to 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27533474" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Enterohemorrhagic Escherichia coli Hybrid Pathotype O80:H2 as a New Therapeutic Challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27533474" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Enterohemorrhagic Escherichia coli Hybrid Pathotype O80:H2 as a New Therapeutic Challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21632020" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Large and ongoing outbreak of haemolytic uraemic syndrome, Germany, May 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7616950" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Community outbreak of hemolytic uremic syndrome attributable to Escherichia coli O111:NM--South Australia 1995.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11466187" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Nationwide study of haemolytic uraemic syndrome: clinical, microbiological, and epidemiological features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20937925" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Hemolytic Uremic Syndrome After an Escherichia coli O111 Outbreak.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19124603" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Shiga toxin 2 targets the murine renal collecting duct epithelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20424866" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9323280" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Post-dysenteric hemolytic uremic syndrome in children during an epidemic of Shigella dysentery in Kwazulu/Natal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19483660" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Undercooked ground beef and person-to-person transmission as major risk factors for sporadic hemolytic uremic syndrome related to Shiga-toxin producing Escherchia coli infections in children in France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23042969" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Neonatal hemolytic uremic syndrome after mother-to-child transmission of a low-pathogenic stx2b harboring shiga toxin-producing Escherichia coli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7574226" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Escherichia coli O157:H7 infection in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12195376" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29054297" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22476204" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Dehydration at admission increased the need for dialysis in hemolytic uremic syndrome children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prognosis of the hemolytic uremic syndrome in children</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Prognosis of the hemolytic uremic syndrome in children</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prognosis of the hemolytic uremic syndrome in children</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30382336" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7931868" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20498239" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24664191" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Neurological involvement in children with E. coli O104:H4-induced hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7724282" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Hemolytic uremic syndrome: MR findings of CNS complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17968789" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Gastrointestinal complications of post-diarrheal hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21809003" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Hemorrhagic colitis in postdiarrheal hemolytic uremic syndrome: retrospective analysis of 54 children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15973523" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Colonic stricture secondary to hemolytic uremic syndrome caused by Escherichia coli O-157.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33819463" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Cardiac Manifestation among Children with Hemolytic Uremic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27659663" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Direct cardiac involvement in childhood hemolytic-uremic syndrome: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7717737" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Myocarditis and haemolytic uraemic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7696120" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cardiac tamponade as a terminal event in the hemolytic uremic syndrome in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19033247" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Cardiac tamponade in diarrhoea-positive haemolytic uraemic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14685841" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Troponin I levels in a hemolytic uremic syndrome patient with severe cardiac failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12644926" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cardiac ischemia during hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3572639" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Exocrine and endocrine pancreatic insufficiency and calcinosis after hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16960711" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Childhood hemolytic uremic syndrome is associated with adolescent-onset diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9709881" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Hemolytic-uremic syndrome following urinary tract infection with enterohemorrhagic Escherichia coli: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21297888" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27240858" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Fecal diagnostics in combination with serology: best test to establish STEC-HUS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30989342" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Hemolytic uremic syndrome in a developing country: Consensus guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23843163" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24317278" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Interaction of Shiga toxin 2 with complement regulators of the factor H protein family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23307876" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
